PhaseBio Pharmaceuticals Inc Contracts & Agreements
57 Contracts & Agreements
- Business Finance (23 contracts)
- Business Operations (5)
- Human Resources (13)
- Intellectual Property (7)
- Real Estate (1)
- Uncategorized (8)
- First Amended Combined Disclosure Statement and Chapter 11 Plan (Filed With SEC on July 12, 2024)
- Plan Support and Settlement Agreement, dated as of March 5, 2024, by and between PhaseBio Pharmaceuticals, Inc. and SFJ Pharmaceuticals X, Inc. (f/k/a SFJ Pharmaceuticals X, Ltd.) (Filed With SEC on March 12, 2024)
- Form of RSU Grant Notice and Award Agreement for 2018 Equity Incentive Plan (Filed With SEC on August 12, 2022)
- Form of RSU Grant Notice and Award Agreement for 2022 Inducement Plan (Filed With SEC on May 16, 2022)
- Form of RSU Grant Notice and Award Agreement for 2018 Equity Incentive Plan (Filed With SEC on May 16, 2022)
- Amendment No. 1, dated November 18, 2021, to Master Services Agreement by and between PhaseBio Pharmaceuticals, Inc. and BioVectra Inc (Filed With SEC on March 24, 2022)
- Severance Benefit Plan and Form of Participation Agreement, as amended (Filed With SEC on March 24, 2022)
- Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 24, 2022)
- Form of RSU Grant Notice and Award Agreement for 2022 Inducement Plan (Filed With SEC on March 24, 2022)
- Form of RSU Grant Notice and Award Agreement for 2018 Equity Incentive Plan (Filed With SEC on March 24, 2022)
- Equity Distribution Agreement, dated November 10, 2021 by and between PhaseBio Pharmaceuticals, Inc. and William Blair & Company, L.L.C (Filed With SEC on November 10, 2021)
- 2018 Equity Incentive Plan (as amended) (Filed With SEC on November 10, 2021)
- Acknowledgement of Grant of a Sublicense in Accordance with the License Agreement between Medimmune Limited and PhaseBio Pharmaceuticals, Inc. and Related Options (Filed With SEC on August 12, 2021)
- License Agreement, dated as of June 16, 2021, by and between PhaseBio Pharmaceuticals, Inc. and Alfasigma, S.p.A (Filed With SEC on August 12, 2021)
- Supply Agreement, dated as (Filed With SEC on May 13, 2021)
- Underwriting Agreement, dated March 17, 2021 (Filed With SEC on March 19, 2021)
- Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 15, 2021)
- Amendment to License Agreement, dated January 9, 2020, by and between PhaseBio Pharmaceuticals, Inc. and MedImmune Limited (Filed With SEC on March 30, 2020)
- Description of PhaseBio Pharmaceuticals, Inc. Common Stock (Filed With SEC on March 30, 2020)
- Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to SFJ Pharmaceuticals X, Ltd. on January 9, 2020 (Filed With SEC on March 30, 2020)
- Co-Development Agreement, dated January 9, 2020, by and between PhaseBio Pharmaceuticals, Inc. and SFJ Pharmaceuticals X, Ltd (Filed With SEC on March 30, 2020)
- Asset Purchase Agreement, dated January 13, 2020, by and between PhaseBio Pharmaceuticals, Inc., Viamet Pharmaceuticals Holdings, LLC and Selenity Therapeutics (Bermuda), Ltd (Filed With SEC on March 30, 2020)
- Form of Program Transfer Agreement by and between PhaseBio Pharmaceuticals Inc. and SFJ Pharmaceuticals X. Ltd (Filed With SEC on March 30, 2020)
- Intellectual Property Security Agreement, dated as of March 19, 2020, by and among PhaseBio Pharmaceuticals, Inc. and Silicon Valley Bank and WestRiver Innovation Lending Fund... (Filed With SEC on March 30, 2020)
- Subordination Agreement, dated as of March 19, 2020, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and SFJ Pharmaceuticals X, Ltd (Filed With SEC on March 30, 2020)
- Consent and First Amendment to Loan and Security Agreement, dated as of March 19, 2020, by and among PhaseBio Pharmaceuticals, Inc. and Silicon Valley Bank and WestRiver... (Filed With SEC on March 30, 2020)
- Non-Employee Director Compensation Policy, as amended (Filed With SEC on February 13, 2020)
- Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on October 2, 2019 (Filed With SEC on November 14, 2019)
- Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on October 2, 2019 (Filed With SEC on November 14, 2019)
- Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on July 26, 2019 (Filed With SEC on August 14, 2019)
- Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on July 26, 2019 (Filed With SEC on August 14, 2019)
- Eighth Amendment to License Agreement, dated as of March 5, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Duke University (Filed With SEC on April 9, 2019)
- Form of Underwriting Agreement (Filed With SEC on April 9, 2019)
- License Agreement, dated April 1, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Wacker Biotech GmbH (Filed With SEC on April 9, 2019)
- Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on March 25, 2019 (Filed With SEC on March 26, 2019)
- Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on March 25, 2019 (Filed With SEC on March 26, 2019)
- Master Services Agreement, dated as of November 14, 2018, by and between PhaseBio Pharmaceuticals, Inc. and BioVectra Inc (Filed With SEC on March 26, 2019)
- Loan and Security Agreement, dated as of March 25, 2019, by and among PhaseBio Pharmaceuticals, Inc. and Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P (Filed With SEC on March 26, 2019)
- Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 4, 2019)
- 2018 Equity Incentive Plan and Forms of Stock Option Grant Notice and Agreement and Restricted Stock Unit Grant Notice and Agreement thereunder (Filed With SEC on October 5, 2018)
- Severance Benefit Plan and Form of Participation Agreement thereunder to be effective upon the closing of this offering (Filed With SEC on October 5, 2018)
- Form of Indemnification Agreement by and between the Registrant and each of its directors and executive officers (Filed With SEC on October 5, 2018)
- Non-Employee Director Compensation Policy to be effective in connection with this offering (Filed With SEC on October 5, 2018)
- 2018 Employee Stock Purchase Plan (Filed With SEC on October 5, 2018)
- Form of Underwriting Agreement (Filed With SEC on October 5, 2018)
- Form of Warrant to Purchase Shares of Series B Redeemable Convertible Preferred Stock, issued by the Registrant on December 22, 2009 (Filed With SEC on September 21, 2018)
- Warrant to Purchase Shares of Series C-1 Redeemable Convertible Preferred Stock, issued by the Registrant to Silicon Valley Bank on October 18, 2017 (Filed With SEC on September 21, 2018)
- Fourth Amended and Restated Investor Rights Agreement by and among the Registrant and certain of its stockholders, dated August 27, 2018 (Filed With SEC on September 21, 2018)
- Amended and Restated 2002 Stock Plan and Form of Option Agreement and Exercise Notice thereunder, as amended to date (Filed With SEC on September 21, 2018)
- Change of Control Severance Benefit Plan and Form of Participation Agreement thereunder (Filed With SEC on September 21, 2018)
- Offer Letter, dated as of November 19, 2012, by and between the Registrant and Jonathan P. Mow, as amended to date (Filed With SEC on September 21, 2018)
- Offer Letter, dated as of March 13, 2016, by and between the Registrant and John Sharp (Filed With SEC on September 21, 2018)
- Offer Letter, dated as of March 30, 2016, by and between the Registrant and John Lee, M.D., Ph.D (Filed With SEC on September 21, 2018)
- License Agreement, dated as of October 18, 2006 and as amended to date, by and between Phase Bioscience, Inc. (predecessor in interest to the Registrant) and Duke University (Filed With SEC on September 21, 2018)
- License Agreement, dated as of November 21, 2017, by and between the Registrant and Medimmune Limited (Filed With SEC on September 21, 2018)
- Loan and Security Agreement, dated as of October 18, 2017 and as amended to date, by and between the Registrant and Silicon Valley Bank (Filed With SEC on September 21, 2018)
- Lease Agreement, dated as of January 15, 2010 and as amended to date, by and between the Registrant and Liberty Property Limited Partnership (Filed With SEC on September 21, 2018)
